MiR-483-5p Promotes Prostate Cancer Cell Proliferation and Invasion by Targeting RBM5

Overview

Journal Int Braz J Urol

Specialty Urology

Date 2017 Jul 21

PMID 28727371

Citations 18

Authors

Zhi-Gang Yang

Xu-Dong Ma

Zhao-Hui He

Ying-Xin Guo

Affiliations

Soon will be listed here.

Abstract

Objective: miR-483-5p has been identified as a miRNA oncogene in certain cancers. However, its role in prostate cancer has not been sufficiently investigated. In this study, we investigated the role of miR-483-5p in prostate cancer and examined RBM5 regulation by miR-483-5p.

Material And Methods: Expression levels of miR-483-5p were determined by quantitative real-time PCR. The effect of miR-483-5p on proliferation was evaluated by MTT assay, cell invasion was evaluated by trans-well invasion assays, and target protein expression was determined by western blotting in LNCaP, DU-145, and PC-3 cells. Luciferase reporter plasmids were constructed to confirm the action of miR-483-5p on downstream target gene RBM5 in HEK-293T cells.

Results: we observed that miR-483-5p was upregulated in prostate cancer cell lines and tissues. A miR-483-5p inhibitor inhibited prostate cancer cell growth and invasion in DU-145 and PC-3 cells. miR-483-5p directly bound to the 3' untranslated region (3'UTR) of RBM5 in HEK-293T cells. RBM5 overexpression inhibited prostate cancer cell growth and invasion in LNCaP cells. Enforced RBM5 expression alleviated miR- 483-5p promotion of prostate cancer cell growth and invasion in LNCaP cells.

Conclusion: The present study describes a potential mechanism underlying a miR-483- 5p/RBM5 link that contributes to prostate cancer development.

Citing Articles

RBM5 suppresses proliferation, metastasis and glycolysis of colorectal cancer cells stabilizing phosphatase and tensin homolog mRNA.

Wang C, Liu F, Wang Y World J Gastrointest Oncol. 2024; 16(7):3241-3255.

PMID: 39072172 PMC: 11271791. DOI: 10.4251/wjgo.v16.i7.3241.

Unveiling the Potential of Serum MiR-483-5p: A Promising Diagnostic and Prognostic Biomarker in OLP and OSCC Patients by Analysis of Differential Gene Expression.

Soltaninezhad P, Arab F, Mohtasham N, FakherBaheri M, Kavishahi N, Aghaee-Bakhtiari S Curr Pharm Des. 2024; 30(4):310-322.

PMID: 38310566 DOI: 10.2174/0113816128276149240108163407.

Circulation microRNA expression profiles in patients with complete responses to chemoradiotherapy in nasopharyngeal carcinoma.

Wardana T, Chasanah S, Oktriani R, Herawati C, Anwar S, Astuti I Noncoding RNA Res. 2022; 7(4):233-241.

PMID: 36203524 PMC: 9519485. DOI: 10.1016/j.ncrna.2022.09.005.

Implication of miR-122, miR-483, and miR-335 Expression Levels as Potential Signatures in HCV-Related Hepatocellular Carcinoma (HCC) in Egyptian Patients.

Elfert A, Salem A, Abdelhamid A, Salama A, Sourour D, Shaker O Front Mol Biosci. 2022; 9:864839.

PMID: 35651814 PMC: 9150846. DOI: 10.3389/fmolb.2022.864839.

Specific nursing improves postoperative urine control function and the self-efficacy of patients undergoing radical prostatectomies.

Jiang J, Du L, Wang X, Huang S, Hu W, Zhou L Am J Transl Res. 2022; 14(3):1695-1704.

PMID: 35422910 PMC: 8991116.

References

Humphries B, Yang C . The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Oncotarget. 2015; 6(9):6472-98. PMC: 4466628. DOI: 10.18632/oncotarget.3052. View

Shao C, Yang B, Zhao L, Wang S, Zhang J, Wang K . Tumor suppressor gene RBM5 delivered by attenuated Salmonella inhibits lung adenocarcinoma through diverse apoptotic signaling pathways. World J Surg Oncol. 2013; 11:123. PMC: 3673837. DOI: 10.1186/1477-7819-11-123. View

Fan S, Chen W, Lv X, Tang Q, Sun L, Liu B . miR-483-5p determines mitochondrial fission and cisplatin sensitivity in tongue squamous cell carcinoma by targeting FIS1. Cancer Lett. 2015; 362(2):183-91. DOI: 10.1016/j.canlet.2015.03.045. View

Wang L, Shi M, Hou S, Ding B, Liu L, Ji X . MiR-483-5p suppresses the proliferation of glioma cells via directly targeting ERK1. FEBS Lett. 2012; 586(9):1312-7. DOI: 10.1016/j.febslet.2012.03.035. View

Valdes-Mora F, Clark S . Prostate cancer epigenetic biomarkers: next-generation technologies. Oncogene. 2014; 34(13):1609-18. DOI: 10.1038/onc.2014.111. View

Chabre O, Libe R, Assie G, Barreau O, Bertherat J, Bertagna X . Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. Endocr Relat Cancer. 2013; 20(4):579-94. DOI: 10.1530/ERC-13-0051. View

Zhang L, Zhang Q, Yang Y, Wu C . The RNA recognition motif domains of RBM5 are required for RNA binding and cancer cell proliferation inhibition. Biochem Biophys Res Commun. 2014; 444(3):445-50. DOI: 10.1016/j.bbrc.2014.01.102. View

Song Q, Xu Y, Yang C, Chen Z, Jia C, Chen J . miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM. Cancer Res. 2014; 74(11):3031-42. DOI: 10.1158/0008-5472.CAN-13-2193. View

McClure T, Margolis D, Hu J . Partial gland ablation in the management of prostate cancer: a review. Curr Opin Urol. 2016; 27(2):156-160. DOI: 10.1097/MOU.0000000000000376. View

10.

Fleshner K, Carlsson S, Roobol M . The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol. 2016; 14(1):26-37. PMC: 5341610. DOI: 10.1038/nrurol.2016.251. View

11.

Qu X, Zhao M, Wu S, Yu W, Xu J, Xu J . Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma. Med Oncol. 2014; 31(10):219. DOI: 10.1007/s12032-014-0219-x. View

12.

Zhao L, Li R, Shao C, Li P, Liu J, Wang K . 3p21.3 tumor suppressor gene RBM5 inhibits growth of human prostate cancer PC-3 cells through apoptosis. World J Surg Oncol. 2012; 10:247. PMC: 3544648. DOI: 10.1186/1477-7819-10-247. View

13.

Bracken C, Scott H, Goodall G . A network-biology perspective of microRNA function and dysfunction in cancer. Nat Rev Genet. 2016; 17(12):719-732. DOI: 10.1038/nrg.2016.134. View

14.

Adams B, Kasinski A, Slack F . Aberrant regulation and function of microRNAs in cancer. Curr Biol. 2014; 24(16):R762-76. PMC: 4177046. DOI: 10.1016/j.cub.2014.06.043. View

15.

Fendler A, Stephan C, Yousef G, Kristiansen G, Jung K . The translational potential of microRNAs as biofluid markers of urological tumours. Nat Rev Urol. 2016; 13(12):734-752. DOI: 10.1038/nrurol.2016.193. View

16.

Li J, Tan S, Kooger R, Zhang C, Zhang Y . MicroRNAs as novel biological targets for detection and regulation. Chem Soc Rev. 2013; 43(2):506-17. DOI: 10.1039/c3cs60312a. View

17.

Schwarzenbach H, Nishida N, Calin G, Pantel K . Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014; 11(3):145-56. DOI: 10.1038/nrclinonc.2014.5. View

18.

Ciccarese C, Massari F, Iacovelli R, Fiorentino M, Montironi R, Di Nunno V . Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. Cancer Treat Rev. 2017; 54:68-73. DOI: 10.1016/j.ctrv.2017.02.001. View

19.

Shen J, Wang A, Wang Q, Gurvich I, Siegel A, Remotti H . Exploration of genome-wide circulating microRNA in hepatocellular carcinoma: MiR-483-5p as a potential biomarker. Cancer Epidemiol Biomarkers Prev. 2013; 22(12):2364-73. PMC: 3963823. DOI: 10.1158/1055-9965.EPI-13-0237. View

20.

Soon P, Tacon L, Gill A, Bambach C, Sywak M, Campbell P . miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer. Clin Cancer Res. 2009; 15(24):7684-7692. DOI: 10.1158/1078-0432.CCR-09-1587. View